Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Current Assets: 2020-2024

Historic Current Assets for Oncology Institute (TOI) over the last 5 years, with FY2024 value amounting to $112.4 million.

  • Oncology Institute's Current Assets fell 543.96% to $110.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $434.1 million, marking a year-over-year decrease of 1608.23%. This contributed to the annual value of $112.4 million for FY2024, which is 2165.61% down from last year.
  • According to the latest figures from FY2024, Oncology Institute's Current Assets is $112.4 million, which was down 2165.61% from $143.5 million recorded in FY2023.
  • Oncology Institute's Current Assets' 5-year high stood at $154.1 million during FY2021, with a 5-year trough of $29.7 million in FY2020.
  • Its 5-year average for Current Assets is $114.0 million, with a median of $130.4 million in 2022.
  • In the last 5 years, Oncology Institute's Current Assets skyrocketed by 41835.8% in 2021 and then plummeted by 2165.61% in 2024.
  • Annual analysis of 5 years shows Oncology Institute's Current Assets stood at $29.7 million in 2020, then surged by 418.36% to $154.1 million in 2021, then dropped by 15.34% to $130.4 million in 2022, then rose by 10.03% to $143.5 million in 2023, then decreased by 21.66% to $112.4 million in 2024.
  • Its Current Assets stands at $112.4 million for FY2024, versus $143.5 million for FY2023 and $130.4 million for FY2022.